Extracellular purines promote the differentiation of human bone marrow-derived mesenchymal stem cells to the osteogenic and adipogenic lineages

Stem Cells and Development

Volumn 22, Issue 7, 2013, Pages 1097-1111

  Ciciarello, Marilena ^a   Zini, Roberta ^b   Rossi, Lara ^a   Salvestrini, Valentina ^a   Ferrari, Davide ^c   Manfredini, Rossella ^b   Lemoli, Roberto M ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c UNIVERSITY OF FERRARA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

5' NUCLEOTIDASE; ADENOSINE TRIPHOSPHATE; CD39 ANTIGEN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PURINE DERIVATIVE; PURINERGIC P2 RECEPTOR;

ADIPOGENESIS; ARTICLE; BONE MARROW CELL; CARTILAGE CELL; CELL DIFFERENTIATION; DEGRADATION; EXTRACELLULAR SPACE; FLOW CYTOMETRY; GENE EXPRESSION; LIPID STORAGE; MESENCHYMAL STEM CELL; MINERALIZATION; OSTEOBLAST; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ADENOSINE; ADENOSINE TRIPHOSPHATE; ADIPOGENESIS; BONE MARROW CELLS; CELL DIFFERENTIATION; CELLS, CULTURED; CORE BINDING FACTOR ALPHA 1 SUBUNIT; HUMANS; MESENCHYMAL STROMAL CELLS; OSTEOGENESIS; PPAR GAMMA; PURINES; RECEPTORS, PURINERGIC P2; RECEPTORS, PURINERGIC P2Y1; SIGNAL TRANSDUCTION;

EID: 84875953983     PISSN: 15473287     EISSN: 15578534     Source Type: Journal    
DOI: 10.1089/scd.2012.0432     Document Type: Article

References (86)

1. Caplan AI. (1991). Mesenchymal stem cells. J Orthop Res 9:641-650.
2. Horwitz EM, K Le Blanc, M Dominici, I Mueller, I Slaper- Cortenbach, FC Marini, RJ Deans, DS Krause and A Keating. (2005). Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement. Cytotherapy 7:393-395.
3. Pittenger MF, AM Mackay, SC Beck, RK Jaiswal, R Douglas, JD Mosca, MA Moorman, DW Simonetti, S Craig and DR Marshak. (1999). Multilineage potential of adult human mesenchymal stem cells. Science 284:143-147.
4. Jiang Y, BN Jahagirdar, RL Reinhardt, RE Schwartz, CD Keene, XR Ortiz-Gonzalez, M Reyes, T Lenvik, T Lund, et al. (2002). Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 418:41-49.
5. Le Blanc K. (2003). Immunomodulatory effects of fetal and adult mesenchymal stem cells. Cytotherapy 5:485-489.
6. Krampera M, S Glennie, J Dyson, D Scott, R Laylor, E Simpson and F Dazzi. (2003). Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigenspecific T cells to their cognate peptide. Blood 101:3722- 3729.
7. Fibbe WE, AJ Nauta and H Roelofs. (2007). Modulation of immune responses by mesenchymal stem cells. Ann N Y Acad Sci 1106:272-278.
8. Uccelli A, L Moretta and V. Pistoia. (2006). Immunoregulatory function of mesenchymal stem cells. Eur J Immunol 36:2566- 2573.
9. Eliopoulos N, J Stagg, L Lejeune, S Pommey and J Galipeau. (2005). Allogeneic marrow stromal cells are immune rejected by MHC class I- and class II-mismatched recipient mice. Blood 106:4057-4065.
10. Poncelet AJ, J Vercruysse, A Saliez and P Gianello. (2007). Although pig allogeneic mesenchymal stem cells are not immunogenic in vitro, intracardiac injection elicits an immune response in vivo. Transplantation 83:783-790.
11. Isakova IA, J Dufour, C Lanclos, J Bruhn and DG Phinney. (2010). Cell-dose-dependent increases in circulating levels of immune effector cells in rhesus macaques following intracranial injection of allogeneic MSCs. Exp Hematol 38: 957-967.e1.
12. Griffin MD, Ritter T and BP Mahon. (2010). Immunological aspects of allogeneic mesenchymal stem cell therapies. Hum Gene Ther 21:1641-1655.
13. Caplan AI. (2007). Adult mesenchymal stem cells for tissue engineering versus regenerative medicine. J Cell Physiol 213:341-347.
14. Lemoli RM, F Bertolini, R Cancedda, M De Luca, A Del Santo, G Ferrari, S Ferrari, G Martino, F Mavilio and S Tura. (2005). Stem cell plasticity: time for a reappraisal? Haematologica 90:360-381.
15. Aluigi M, M Fogli, A Curti, A Isidori, E Gruppioni, C Chiodoni, MP Colombo, P Versura, A D'Errico-Grigioni, et al. (2006). Nucleofection is an efficient nonviral transfection technique for human bone marrow-derived mesenchymal stem cells. Stem Cells 24:454-461.
16. Sensebé L, M Krampera, H Schrezenmeier, P Bourin and R Giordano. (2010). Mesenchymal stem cells for clinical application. Vox Sang 98:93-107.
17. Ryten M, PM Dunn, JT Neary and G Burnstock. (2002). ATP regulates the differentiation of mammalian skeletal muscle by activation of a P2X5 receptor on satellite cells. J Cell Biol 158:345-355.
18. Sak K, JM Boeynaems and H Everaus. (2003). Involvement of P2Y receptors in the differentiation of haematopoietic cells. J Leukoc Biol 73:442-447.
19. Burnstock G. (2006). Historical review: ATP as a neurotransmitter. Trends Pharmacol Sci 27:166-176.
20. Gachet C. (2008). P2 receptors, platelet function and pharmacological implications. Thromb Haemost 99:466-472.
21. Bours MJ, EL Swennen, F Di Virgilio, BN Cronstein and PC Dagnelie. (2006). Adenosine 5'-triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation. Pharmacol Ther 112:358-404.
22. Di Virgilio F. (2012). Purines, purinergic receptors, and cancer. Cancer Res 72:5441-5447.
23. Burnstock G, GE Knight and AV Greig. (2012). Purinergic signaling in healthy and diseased skin. J Invest Dermatol 132:526-546.
24. Ralevic V and G. Burnstock. (1998). Receptors for purines and pyrimidines. Pharmacol Rev 50:413-492.
25. Abbracchio MP, G Burnstock, JM Boeynaems, EA Barnard, JL Boyer, C Kennedy, GE Knight, M Fumagalli, C Gachet, KA Jacobson and GA Weisman. (2006). International Union of Pharmacology LVIII: update on the P2Y G proteincoupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy. Pharmacol Rev 58: 281-341.
26. Burnstock G. (2007). Purine and pyrimidine receptors. Cell Mol Life Sci 64:1471-1483.
27. Zimmermann H. (2000). Extracellular metabolism of ATP and other nucleotides. Naunyn Schmiedebergs Arch Pharmacol 362:299-309.
28. Yegutkin GG. (2008). Nucleotide- and nucleoside-converting ectoenzymes: important modulators of purinergic signalling cascade. Biochim Biophys Acta 1783:673-694.
29. Shryock JC and L Belardinelli. (1997). Adenosine and adenosine receptors in the cardiovascular system: biochemistry, physiology, and pharmacology. Am J Cardiol 79:2-10.
30. Fredholm BB. (2007). Adenosine, an endogenous distress signal, modulates tissue damage and repair. Cell Death Differ 14:1315-1323.
31. Fredholm BB. (2010). Adenosine receptors as drug targets. Exp Cell Res 316:1284-1288.
32. Fredholm BB, AP IJzerman, KA Jacobson, KN Klotz and J Linden. (2011). International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors-an update. Pharmacol Rev 63:1-34.
33. Ferrari D, S Gulinelli, V Salvestrini, G Lucchetti, R Zini, R Manfredini, L Caione, W Piacibello, M Ciciarello, et al. (2011). Purinergic stimulation of human mesenchymal stem cells potentiates their chemotactic response to CXCL12 and increases the homing capacity and production of proinflammatory cytokines. Exp Hematol 39:360-374.
34. LemoliRM, D Ferrari,MFogli, L Rossi, C Pizzirani, S Forchap, P Chiozzi, D Vaselli, F Bertolini, et al. (2004). Extracellular nucleotides are potent stimulators of human hematopoietic stem cells in vitro and in vivo. Blood 104:1662-1670.
35. Rossi L, R Manfredini, F Bertolini, D Ferrari, M Fogli, R Zini, S Salati, V Salvestrini, S Gulinelli, et al. (2007). The extracellular nucleotide UTP is a potent inducer of hematopoietic stem cell migration. Blood 109:533-542.
36. Salvestrini V, R Zini, L Rossi, S Gulinelli, R Manfredini, E Bianchi, W Piacibello, L Caione, G Migliardi, et al. (2012). Purinergic signaling inhibits human acute myeloblastic leukemia cell proliferation, migration, and engraftment in immunodeficient mice. Blood 119:217-226.
37. Livak KJ and TD Schmittgen. (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25:402-408.
38. Otto F, AP Thornell, T Crompton, A Denzel, KC Gilmour, IR Rosewell, GW Stamp, RS Beddington, S Mundlos, et al. (1997). Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell 89:765-771.
39. Siqueira MF, S Flowers, R Bhattacharya,D Faibish, Y Behl, DN Kotton, L Gerstenfeld, EMoran andDTGraves. (2011). FOXO1 modulates osteoblast differentiation. Bone 48:1043-1051.
40. Kim HJ, T Minashima, EF McCarthy, JA Winkles and T Kirsch. (2010). Progressive ankylosis protein (ANK) in osteoblasts and osteoclasts controls bone formation and bone remodeling. J Bone Miner Res 25:1771-1783.
41. Komori T. (2010). Regulation of bone development and extracellular matrix protein genes by RUNX2. Cell Tissue Res 339:189-195.
42. Lavery K, P Swain, D Falb and MH Alaoui-Ismaili. (2008). BMP-2/4 and BMP-6/7 differentially utilize cell surface receptors to induce osteoblastic differentiation of human bone marrow-derived mesenchymal stem cells. J Biol Chem 283:20948-20958.
43. Si W, Q Kang, HH Luu, JK Park, Q Luo, WX Song, W Jiang, X Luo, X Li, et al. (2006). CCN1/Cyr61 is regulated by the canonical Wnt signal and plays an important role in Wnt3Ainduced osteoblast differentiation of mesenchymal stem cells. Mol Cell Biol 26:2955-2964.
44. Schedlich LJ, A Muthukaruppan, MK O'Han and RC Baxter. (2007). Insulin-like growth factor binding protein-5 interacts with the vitamin D receptor and modulates the vitamin D response in osteoblasts. Mol Endocrinol 21:2378-2390.
45. Giustina A, G Mazziotti and E Canalis. (2008). Growth hormone, insulin-like growth factors, and the skeleton. Endocr Rev 29:535-559.
46. Farmer SR. (2006). Transcriptional control of adipocyte formation. Cell Metab 4:263-273.
47. Chang BH, L Li, A Paul, S Taniguchi, V Nannegari, WC Heird and L Chan. (2006). Protection against fatty liver but normal adipogenesis in mice lacking adipose differentiationrelated protein. Mol Cell Biol 26:1063-1076.
48. Zhang J, WL Xia and F Ahmad. (1995). Regulation of pyruvate carboxylase in 3T3-L1 cells. Biochem J 306:205-210.
49. Eastman SW, M Yassaee and PD Bieniasz. (2009). A role for ubiquitin ligases and Spartin/SPG20 in lipid droplet turnover. J Cell Biol 184:881-894.
50. Jacques C, AD Recklies, A Levy and F Berenbaum. (2007). HC-gp39 contributes to chondrocyte differentiation by inducing SOX9 and type II collagen expressions. Osteoarthritis Cartilage 15:138-146.
51. Baldridge D, J Lennington, M Weis, EP Homan, Jiang MM, E Munivez, DR Keene, WR Hogue, S Pyott, et al. (2010). Generalized connective tissue disease in Crtap-/- mouse. PLos One 5:e10560.
52. Combs TP, JA Wagner, J Berger, T Doebber, WJ Wang, BB Zhang, M Tanen, AH Berg, S O'Rahilly, et al. (2002). Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization. Endocrinology 143:998- 1007.
53. Park SK, SY Oh, MY Lee, S Yoon, KS Kim and JW Kim. (2004). CCAAT/enhancer binding protein and nuclear factor- Y regulate adiponectin gene expression in adipose tissue. Diabetes 53:2757-2766.
54. Wellner M, F Herse, J Janke, K Gorzelniak, S Engeli, D Bechart, P Lasalle, FC Luft and AM Sharma. (2003). Endothelial cell specific molecule-1-a newly identified protein in adipocytes. Horm Metab Res 35:217-221.
55. Gonĉalves CA, MC Leite and MC Guerra. (2010). Adipocytes as an important source of serum S100B and possible roles of this protein in adipose tissue. Cardiovasc Psychiatry Neurol 2010:790431.
56. Moldes M, F Lasnier, B Fève, J Pairault and P Djian. (1997). Id3 prevents differentiation of preadipose cells. Mol Cell Biol 17:1796-1804.
57. Boland GM, G Perkins, DJ Hall and RS Tuan. (2004). Wnt 3a promotes proliferation and suppresses osteogenic differentiation of adult human mesenchymal stem cells. J Cell Biochem 93:1210-1230.
58. Rajalin AM and P Aarnisalo. (2011). Cross-talk between NR4A orphan nuclear receptors and b-catenin signaling pathway in osteoblasts. Arch Biochem Biophys 509:44-51.
59. Chan TF, D Couchourel, E Abed, A Delalandre, N Duval and D. Lajeunesse. (2011). Elevated Dickkopf-2 levels contribute to the abnormal phenotype of human osteoarthritic osteoblasts. J Bone Miner Res 26:1399-1410.
60. Yao W, Z Cheng, M Shahnazari, W Dai, ML Johnson and NE Lane. (2010). Overexpression of secreted frizzledrelated protein 1 inhibits bone formation and attenuates parathyroid hormone bone anabolic effects. J Bone Miner Res 25:190-199.
61. Cho HY, HJ Choi, HJ Sun, et al. (2010). Transgenic mice overexpressing secreted frizzled-related proteins (sFRP)4 under the control of serum amyloid P promoter exhibit low bone mass but did not result in disturbed phosphate homeostasis. Bone 47:263-271.
62. Murray SS, MS Grisanti, GV Bentley, AJ Kahn, MR Urist and EJ Murray. (1997). The calpain-calpastatin system and cellular proliferation and differentiation in rodent osteoblastic cells. Exp Cell Res 233:297-309.
63. Ouyang X, M Fujimoto, R Nakagawa, S Serada, T Tanaka, S Nomura, I Kawase, T Kishimoto and T Naka. (2006). SOCS-2 interferes with myotube formation and potentiates osteoblast differentiation through upregulation of JunB in C2C12 cells. J Cell Physiol 207:428-436.
64. Yoshiko Y, N Maeda and JE Aubin. (2003). Stanniocalcin 1 stimulates osteoblast differentiation in rat calvaria cell cultures. Endocrinology 144:4134-4143.
65. Cornish J, MT Gillespie, KE Callon, NJ Horwood, JM Moseley and IR Reid. (2003). Interleukin-18 is a novel mitogen of osteogenic and chondrogenic cells. Endocrinology 144:1194-1201.
66. Gordon JA, MQ Hassan, M Koss, M Montecino, L Selleri, AJ van Wijnen, JL Stein, GS Stein, and JB Lian. (2011). Epigenetic regulation of early osteogenesis and mineralized tissue formation by a HOXA10-PBX1-associated complex. Cells Tissues Organs 194:146-150.
67. Fortunati D, S Reppe, AK Fjeldheim, M Nielsen, VT Gautvik and KM Gautvik. (2010). Periostin is a collagen associated bone matrix protein regulated by parathyroid hormone. Matrix Biol 29:594-601.
68. Billiard J, RA Moran, MZ Whitley, M Chatterjee-Kishore, K Gillis, EL Brown, BS Komm and PV Bodine. (2003). Transcriptional profiling of human osteoblast differentiation. J Cell Biochem 89:389-400.
69. Billiard J, DS Way, LM Seestaller-Wehr, RA Moran, A Mangine and PV Bodine. (2005). The orphan receptor tyrosine kinase Ror2 modulates canonical Wnt signaling in osteoblastic cells. Mol Endocrinol 19:90-101.
70. Nistala H, S Lee-Arteaga, S Smaldone, G Siciliano, L Carta, RN Ono, G Sengle, E Arteaga-Solis, R Levasseur, et al. (2010). Fibrillin-1 and -2 differentially modulate endogenous TGF-b and BMP bioavailability during bone formation. J Cell Biol 190:1107-1121.
71. Spiegelman BM, E Hu, JB Kim and R Brun. (1997). PPAR gamma and the control of adipogenesis. Biochimie 79:111-112.
72. Sattler C, M Steinsdoerfer, M Offers, E Fischer, R Schierl, K Heseler, W Däubener and J Seissler. (2011). Inhibition of T cell proliferation by murine multipotent mesenchymal stromal cells is mediated by CD39 expression and adenosine generation. Cell Transplant 20:1221-1230.
73. Saldanha-Araujo F, FI Ferreira, PV Palma, AG Araujo, RH Queiroz, DT Covas, MA Zago and RA Panepucci. (2011). Mesenchymal stromal cells upregulate CD39 and increase adenosine production to suppress activated T-lymphocytes. Stem Cell Res 7:66-74.
74. Sundin M, P D'arcy, CC Johansson, AJ Barrett, H Lönnies, B Sundberg, S Nava, R Kiessling, D Mougiakakos and K Le Blanc. (2011). Multipotent mesenchymal stromal cells express FoxP3: a marker for the immunosuppressive capacity? J Immunother 34:336-342.
75. Murayama T, T Katada and M Ui. (1983). Guanine nucleotide activation and inhibition of adenylate cyclase as modified by islet-activating protein, pertussis toxin, in mouse 3T3 fibroblasts. Arch Biochem Biophys 221:381-390.
76. Evans BA, C Elford, A Pexa, K Francis, AC Hughes, A Deussen and J Ham. (2006). Human osteoblast precursors produce extracellular adenosine, which modulates their secretion of IL-6 and osteoprotegerin. J Bone Miner Res 21:228-236.
77. Carroll SH, NA Wigner, N Kulkarni, H Johnston-Cox, LC Gerstenfeld and K Ravid. (2012). A2B adenosine receptor promotes mesenchymal stem cell differentiation to osteoblasts and bone formation in vivo. J Biol Chem 287:15718- 15727.
78. Orriss IR, G Burnstock and TR Arnett. (2010). Purinergic signalling and bone remodelling. Curr Opin Pharmacol 10:322-330.
79. Vassaux G, D Gaillard, B Mari, G Ailhaud and R Negrel. (1993). Differential expression of adenosine A1 and A2 receptors in preadipocytes and adipocytes. Biochem Biophys Res Commun 193:1123-1130.
80. Børglum JD, G Vassaux, B Richelsen, D Gaillard, C Darimont, G Ailhaud and R Negrel. (1996). Changes in adenosine A1- and A2-receptor expression during adipose cell differentiation. Mol Cell Endocrinol 117:17-25.
81. Omatsu-Kanbe M, K Inoue, Y Fujii, T Yamamoto, T Isono, N Fujita and H Matsuura. (2006). Effect of ATP on preadipocyte migration and adipocyte differentiation by activating P2Y receptors in 3T3-L1 cells. Biochem J 393:171-180.
82. Krampera M, G Pizzolo, G Aprili and M.Franchini (2006). Mesenchymal stem cells for bone, cartilage, tendon and skeletal muscle repair. Bone 39:678-683.
83. Shapiro F. (2008). Bone development and its relation to fracture repair. The role of mesenchymal osteoblasts and surface osteoblasts. Eur Cell Mater 15:53-76.
84. Takedachi M, H Oohara, BJ Smith, M Iyama, M Kobashi, K Maeda, CL Long, MB Humphrey, BJ Stoecker, et al. (2012). CD73-generated adenosine promotes osteoblast differentiation. J Cell Physiol 227:2622-2631.
85. Trabanelli S, D Ocadl?́ková, S Gulinelli, A Curti, V Salvestrini, R de Paula Vieira, M Idzko, F Di Virgilio, D Ferrari and RM Lemoli. (2012). Extracellular ATP exerts opposite effects on activated and regulatory CD4 + T cells via purinergic P2 receptor activation. J Immunol 189:1303-1310.
86. Pellegatti P, L Raffaghello, G Bianchi, F Piccardi, V Pistoia and F Di Virgilio. (2008). Increased level of extracellular ATP at tumor sites: in vivo imaging with plasma membrane luciferase. PLoS One 3:e2599.